A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors

Inclusion Criteria:

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Life expectancy at least 12 weeks

- Adequate hematologic and end organ function

- Negative pregnancy test and willingness to utilize contraception among women of
childbearing potential

- Locally advanced, recurrent, or metastatic incurable solid malignancy with measurable
disease per RECIST v1.1

- Progression following at least one standard therapy; or standard therapy considered
ineffective, intolerable, or inappropriate; or use of an investigational agent
recognized as a standard of care

- For the expansion stage, histologically confirmed renal cell cancer (RCC), urothelial
bladder cancer (UBC), triple-negative breast cancer (TNBC), non-small cell lung cancer
(NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), gastric cancer,
ovarian cancer, cervical cancer, endometrial cancer, or Merkel cell cancer

- For the expansion stage, evaluable for PD-L1 expression

- Anti PD-1/PD-L1 relapsed cohorts (I and II), participants whose most recent
anti-cancer therapy consisted of single-agent PD-1/PD-L1 blockade will be enrolled

Exclusion Criteria:

- Significant cardiovascular or liver disease

- Major surgery within 28 days of study drug

- Any anti-cancer therapy within 3 weeks of study drug

- Malabsorption syndrome or poor upper gastrointestinal integrity

- Primary central nervous system (CNS) malignancy or active metastases within 5 years

- Uncontrolled tumor pain

- Autoimmune disease other than stable hypothyroidism or vitiligo

- Human immunodeficiency virus (HIV), active hepatitis B or C, or tuberculosis

- Signs/symptoms of infection, or use of antibiotics within 2 weeks of study drug

- Live attenuated vaccine within 4 weeks of study drug

- Known history or predisposition to QT interval prolongation

- Prior cancer immunotherapy, specifically indoleamine 2,3-dioxygenase (IDO) or
tryptophan 2,3-dioxygenase (TDO) inhibitors, T-cell costimulatory receptor agonist
antibodies, or checkpoint inhibitors among certain participants